isa-51
Small moleculeexperimental
Clinical trial activity
11 trials · 14 clinical orgs · 0 marketing orgs
Phase 1
9
Phase 2
6
Phase 3
0
Phase 4
0
Earliest trial started Mar 7, 2005 (NCT00295581)
Timeline
Indications
Studied for
- Breast Neoplasms · Phase 1
- Carcinoma · Phase 1/Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 1/Phase 2
- Dermatomyositis · Phase 2
- Esophageal Neoplasms · Phase 1/Phase 2
- Healthy Volunteers · Phase 1
- Infections · Phase 1
- Influenza, Human · Phase 1/Phase 2
- Ischemic Stroke · Phase 1
- Lupus Erythematosus, Systemic · Phase 2
- Malaria, Vivax · Phase 1
- Multiple Myeloma · Phase 1/Phase 2
- Neoplasms · Phase 1/Phase 2
- Plasmodium falciparum · Phase 1
- Vector Borne Diseases · Phase 1
Mechanism of action
- UnclearImmunity, active
Unclear immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- isa51
- isa 51
- isa-51
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06746688 | Phase 1 | Dec 31, 2024 | Expres2ion Biotechnologies APS, Gouya Insights, KKS MedUni Vienna |
| NCT05898828 | Phase 1/Phase 2 (Phase 2) | Jan 3, 2024 | National Cancer Institute (NCI) |
| NCT05642195 | Phase 1/Phase 2 (Phase 2) | Dec 29, 2022 | National Cancer Institute (NCI) |
| NCT04009824 | Phase 1 | Jul 8, 2019 | National Institute of Allergy and Infectious Diseases (NIAID), SEEK, University of Maryland |
| NCT03055000 | Phase 1 | Feb 15, 2017 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT02980198 | Phase 2 | Nov 1, 2016 | Neovacs |
| NCT02665364 | Phase 2 | Sep 1, 2015 | Neovacs, Université catholique de Louvain |
| NCT01272466 | Phase 1/Phase 2 (Phase 2) | Feb 1, 2010 | University of Copenhagen, University of Southern Denmark |
| NCT01010737 | Phase 1/Phase 2 (Phase 2) | Sep 1, 2009 | BiondVax Pharmaceuticals, Tel Aviv University |
| NCT01081847 | Phase 1 | Jul 1, 2005 | Malaria Vaccine and Drug Development Center |
| NCT00295581 | Phase 1 | Mar 7, 2005 | National Institute of Allergy and Infectious Diseases (NIAID) |
Showing 11 of 11 trials
Page 1 / 1
Organizations
Research & Development (14)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 3 | 3 | 1 | 2005 |
| National Cancer Institute (NCI) | Government | 2 | 2 | 1 | 2022 |
| Neovacs | For profit | 2 | 2 | 1 | 2015 |
| BiondVax Pharmaceuticals | For profit | 1 | 1 | 1 | 2009 |
| Expres2ion Biotechnologies APS | For profit | 1 | 1 | 1 | 2024 |
| Gouya Insights | For profit | 1 | 0 | 1 | 2024 |
| KKS MedUni Vienna | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Malaria Vaccine and Drug Development Center | Academic/Hospital | 1 | 1 | 1 | 2005 |
| SEEK | For profit | 1 | 0 | 1 | 2019 |
| Tel Aviv University | Academic/Hospital | 1 | 0 | 1 | 2009 |
| Université catholique de Louvain | Academic/Hospital | 1 | 0 | 1 | 2015 |
| University of Copenhagen | Academic/Hospital | 1 | 1 | 1 | 2010 |
| University of Maryland | Academic/Hospital | 1 | 0 | 1 | 2019 |
| University of Southern Denmark | Academic/Hospital | 1 | 0 | 1 | 2010 |
14 organizations
Page 1 / 1